Alligator Bioscience is a Lund-based clinical-stage immuno-oncology company developing antibody-based therapies to activate the immune system against cancer. Its lead candidate mitazalimab targets CD40 and is in development for pancreatic cancer — one of the hardest-to-treat cancers. Listed on Nasdaq Stockholm, Alligator raised SEK 91 million in December 2025 and has restructured to 11 employees focused entirely on advancing mitazalimab to proof of concept.
alligatorbioscience.sePart of: Skåne Startup map